Concord Biotech Ltd vs Oxygenta Pharmaceutical Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Concord Biotech Ltd is ₹ 1140 as of 30 Apr 15:30 . The P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 47.2 on March 2025 . This represents a CAGR of -4.45% over 2 yearsThe P/E Ratio of Oxygenta Pharmaceutical Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 17537 crore on March 2025 . This represents a CAGR of 4.95% over 2 yearsThe Market Cap of Oxygenta Pharmaceutical Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Concord Biotech Ltd for the Dec '25 is ₹ 287.74 crore as compare to the Sep '25 revenue of ₹ 262.7 crore. This represent the growth of 9.53% The revenue of Oxygenta Pharmaceutical Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Concord Biotech Ltd for the Dec '25 is ₹ 104.98 crore as compare to the Sep '25 ebitda of ₹ 104.13 crore. This represent the growth of 0.82% The ebitda of Oxygenta Pharmaceutical Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Concord Biotech Ltd changed from ₹ 59.59 crore to ₹ 63.64 crore over 7 quarters. This represents a CAGR of 3.83% The net profit of Oxygenta Pharmaceutical Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Concord Biotech Ltd changed from 2.73 % on March 2022 to 24.54 % on March 2025 . This represents a CAGR of 73.15% over 4 yearsThe Dividend Payout of Oxygenta Pharmaceutical Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Concord Biotech Ltd

Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

About Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Limited was initially incorporated as S S Organics Private Limited as a private limited Company in 1990.
The Company converted its status to a Public Limited Company in 1993 changing the name to S S Organics Limited.
Further, it was changed to Oxygenta Pharmaceutical Limited in FY 2021-22. The Company was incorporated with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals.
It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs.
The Company has plant located at Medak in Andhra Pradesh. The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs.

FAQs for the comparison of Concord Biotech Ltd and Oxygenta Pharmaceutical Ltd

Which company has a larger market capitalization, Concord Biotech Ltd or Oxygenta Pharmaceutical Ltd?

Market cap of Concord Biotech Ltd is 11,927 Cr while Market cap of Oxygenta Pharmaceutical Ltd is 200 Cr

What are the key factors driving the stock performance of Concord Biotech Ltd and Oxygenta Pharmaceutical Ltd?

The stock performance of Concord Biotech Ltd and Oxygenta Pharmaceutical Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Biotech Ltd and Oxygenta Pharmaceutical Ltd?

As of May 3, 2026, the Concord Biotech Ltd stock price is INR ₹1140.15. On the other hand, Oxygenta Pharmaceutical Ltd stock price is INR ₹54.34.

How do dividend payouts of Concord Biotech Ltd and Oxygenta Pharmaceutical Ltd compare?

To compare the dividend payouts of Concord Biotech Ltd and Oxygenta Pharmaceutical Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.